Log in to search using one of your social media accounts:

 

Amantadine ER Curbs Levodopa-Induced Dyskinesia in PDAmantadine ER Curbs Levodopa-Induced Dyskinesia in PD

An investigational extended-release formulation of amantadine with a unique chronotherapeutic pharmacokinetic profile eases levodopa-induced dyskinesia in a phase 2/3 study. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Related Links:

Conclusion: Caffeine did not provide clinically important improvement of motor manifestations of PD (Class I evidence). Epidemiologic links between caffeine and lower PD risk do not appear to be explained by symptomatic effects. Clinicaltrials.gov identifier: NCT01738178. Classification of evidence: This study provides Class I evidence that for patients with PD, caffeine does not significantly improve motor manifestations.
Source: Neurology - Category: Neurology Authors: Tags: Parkinson's disease/Parkinsonism ARTICLE Source Type: research
We look at dyskinesia, including the main symptoms and treatment options. Learn more about this condition that results in involuntary movements here.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news
This article addresses the prevalence, risk factors, and prevention of TD; assessment strategies including diagnostic criteria and rating scales; and evidence for TD treatments, including 2 newly approved medications: deutetrabenazine and valbenazine. PMID: 29022654 [PubMed - as supplied by publisher]
Source: Journal of Clinical Psychiatry - Category: Psychiatry Tags: J Clin Psychiatry Source Type: research
Sensors, Vol. 17, Pages 2341: Verification of a Method for Measuring Parkinson’s Disease Related Temporal Irregularity in Spiral Drawings Sensors doi: 10.3390/s17102341 Authors: Somayeh Aghanavesi Mevludin Memedi Mark Dougherty Dag Nyholm Jerker Westin Parkinson’s disease (PD) is a progressive movement disorder caused by the death of dopamine-producing cells in the midbrain. There is a need for frequent symptom assessment, since the treatment needs to be individualized as the disease progresses. The aim of this paper was to verify and further investigate the clinimetric properties of an entropy-...
Source: Sensors - Category: Biotechnology Authors: Tags: Article Source Type: research
The prevalence of gallstones is 10% to 15% in adults. Individuals with acute cholecystitis present with right upper quadrant pain, fever, and leukocytosis. Management includes supportive care and cholecystectomy. The prevalence of choledocholithiasis is 10% to 20%, and serious complications include cholangitis and gallstone pancreatitis. The goal of management in individuals with choledocholithiasis consists of clearing common bile duct stones. Acute ascending cholangitis is a life-threatening condition involving acute inflammation and infection of the common bile duct. Treatment includes intravenous fluids, analgesia, int...
Source: Primary Care: Clinics in Office Practice - Category: Primary Care Authors: Source Type: research
First and only TD therapy taken as one capsule, once per day; new 80 mg capsule expected to be available for patients within two weeks INBRACE™ program offers patients access to treatment and patient assistance SAN DIEGO, Oct. 5, 2017 -- (Healthcare ... Biopharmaceuticals, Neurology, FDA Neurocrine Biosciences, INGREZZA, valbenazine, tardive dyskinesia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Authors: Müller T Abstract Introduction Chronic intake of typical neuroleptics or centrally acting dopamine receptor blocking antiemetics may cause onset of tardive syndromes. Various types exist. One of them is tardive dyskinesia, characterised by often stigmatising, purposeless, rapid, repetitive, stereotypic, involuntary movements of face, limbs or trunk. Effective symptomatic drug treatment options beyond application of tetrabenazine are rare. Tetrabenazine is usually administered three times daily due to the short half life of this agent. Areas covered This narrative review discusses the value of valbenazine...
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research
Authors: Caroff SN, Aggarwal S, Yonan C Abstract Up to 30% of patients taking antipsychotics may develop tardive dyskinesia (TD). Recent evidence-based recommendations demonstrate an unmet need for effective TD management. This systematic review was designed to update the evidence for TD treatment, comparing two vesicular monoamine transporter 2 (VMAT2) inhibitors, tetrabenazine and valbenazine. Of 487 PubMed/Embase search results, 11 studies met the review criteria. Valbenazine efficacy was demonstrated in rigorously designed clinical trials that meet the guidelines for AAN Class I evidence. Due to differences in ...
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
In this report and video, we present a figure-of-8 reconstruction technique to reduce and stabilize a posterior dislocation of the sternoclavicular joint using a gracilis autograft. Ultimately, this reconstruction technique can be performed in a safe, efficient, and reliable manner when appropriate surgical steps are followed.
Source: Arthroscopy Techniques - Category: Surgery Source Type: research
ConclusionsDeutetrabenazine is the second FDA‐approved agent specifically indicated for the treatment of TD. Head‐to‐head comparisons with other VMAT2 inhibitors among patients with TD in the “real world” are needed.
Source: International Journal of Clinical Practice - Category: Internal Medicine Authors: Tags: SYSTEMATIC REVIEW Source Type: research
More News: Amantadine | Brain | Carbidopa/Levodopa | Dyskinesia | Health | Neurology | Neurosurgery | Study | Symmetrel